Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., (Glenmark) is all set to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. Glenmark’s Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin 2 Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), of Fresenius Kabi USA, LLC NDA - 020533. Glenmark will begin distribution in November 2025.
According to IQVIA sales data for the 12-month period ending August 2025, the Naropin Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) market achieved annual sales of around $20.9 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
